Literature DB >> 26026924

Towards a new understanding of NCL pathogenesis.

Jonathan D Cooper1, Marta A Tarczyluk2, Hemanth R Nelvagal2.   

Abstract

The Neuronal Ceroid Lipofuscinoses (NCLs, Batten disease) are a group of inherited neurodegenerative disorders that have been traditionally grouped together on the basis of certain shared clinical and pathological features. However, as the number of genes that appear to cause new forms of NCL continues to grow, it is timely to reassess our understanding of the pathogenesis of these disorders and what groups them together. The various NCL subtypes do indeed share features of a build-up of autofluorescent storage material, progressive neuron loss and activation of the innate immune system. The characterisation of animal models has highlighted the selective nature of neuron loss and its intimate relationship with glial activation, rather than the generalised build-up of storage material. More recent data provide evidence for the pathway-dependent nature of pathology, the contribution of glial dysfunction, and the involvement of new brain regions previously thought to be unaffected, and it is becoming apparent that pathology extends beyond the brain. These data have important implications, not just for therapy, but also for our understanding of these disorders. However, looking beneath these broadly similar pathological themes evidence emerges for marked differences in the nature and extent of these events in different forms of NCL. Indeed, given the widely different nature of the mutated gene products it is perhaps more surprising that these disorders resemble each other as much as they do. Such data raise the question whether we should rethink the collective grouping of these gene deficiencies together, or whether it would be better to consider them as separate entities. This article is part of a Special Issue entitled: Current Research on the Neuronal Ceroid Lipofuscinoses (Batten Disease).
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Glial dysfunction; Neuronal ceroid lipofuscinosis; Pathogenesis; Selective neuron loss; Storage material accumulation

Year:  2015        PMID: 26026924     DOI: 10.1016/j.bbadis.2015.05.014

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  28 in total

1.  Gemfibrozil, food and drug administration-approved lipid-lowering drug, increases longevity in mouse model of late infantile neuronal ceroid lipofuscinosis.

Authors:  Arunava Ghosh; Suresh Babu Rangasamy; Khushbu K Modi; Kalipada Pahan
Journal:  J Neurochem       Date:  2017-04-03       Impact factor: 5.372

2.  Progress toward Fulfilling the Potential of Immunomodulation in Childhood Neurodegeneration?

Authors:  Jonathan D Cooper; Hemanth R Nelvagal
Journal:  Mol Ther       Date:  2017-06-16       Impact factor: 11.454

Review 3.  Recent Insight into the Genetic Basis, Clinical Features, and Diagnostic Methods for Neuronal Ceroid Lipofuscinosis.

Authors:  Konrad Kaminiów; Sylwia Kozak; Justyna Paprocka
Journal:  Int J Mol Sci       Date:  2022-05-20       Impact factor: 6.208

Review 4.  Lysosomal storage diseases.

Authors:  Frances M Platt; Alessandra d'Azzo; Beverly L Davidson; Elizabeth F Neufeld; Cynthia J Tifft
Journal:  Nat Rev Dis Primers       Date:  2018-10-01       Impact factor: 52.329

5.  Longitudinal In Vivo Monitoring of the CNS Demonstrates the Efficacy of Gene Therapy in a Sheep Model of CLN5 Batten Disease.

Authors:  Nadia L Mitchell; Katharina N Russell; Martin P Wellby; Hollie E Wicky; Lucia Schoderboeck; Graham K Barrell; Tracy R Melzer; Steven J Gray; Stephanie M Hughes; David N Palmer
Journal:  Mol Ther       Date:  2018-07-17       Impact factor: 11.454

6.  Self-Complementary AAV9 Gene Delivery Partially Corrects Pathology Associated with Juvenile Neuronal Ceroid Lipofuscinosis (CLN3).

Authors:  Megan E Bosch; Amy Aldrich; Rachel Fallet; Jessica Odvody; Maria Burkovetskaya; Kaitlyn Schuberth; Julie A Fitzgerald; Kevin D Foust; Tammy Kielian
Journal:  J Neurosci       Date:  2016-09-14       Impact factor: 6.167

7.  Synergistic effects of treating the spinal cord and brain in CLN1 disease.

Authors:  Charles Shyng; Hemanth R Nelvagal; Joshua T Dearborn; Jaana Tyynelä; Robert E Schmidt; Mark S Sands; Jonathan D Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-03       Impact factor: 11.205

8.  Neuron-astrocyte interactions in neurodegenerative diseases: Role of neuroinflammation.

Authors:  Kakulavarapu V Rama Rao; Tammy Kielian
Journal:  Clin Exp Neuroimmunol       Date:  2015-08-03

9.  Astrocytes in juvenile neuronal ceroid lipofuscinosis (CLN3) display metabolic and calcium signaling abnormalities.

Authors:  Megan E Bosch; Tammy Kielian
Journal:  J Neurochem       Date:  2018-08-16       Impact factor: 5.372

10.  Cln1-mutations suppress Rab7-RILP interaction and impair autophagy contributing to neuropathology in a mouse model of infantile neuronal ceroid lipofuscinosis.

Authors:  Chinmoy Sarkar; Tamal Sadhukhan; Maria B Bagh; Abhilash P Appu; Goutam Chandra; Avisek Mondal; Arjun Saha; Anil B Mukherjee
Journal:  J Inherit Metab Dis       Date:  2020-04-27       Impact factor: 4.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.